EU Drug Regulator Panel Endorses Eight New Medicines for Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- New Drug Approvals: The EU drug regulator's expert panel endorsed eight new medicines this week, including Merck's Keytruda and AstraZeneca's Enhertu, indicating a positive outlook for cancer treatment advancements that could enhance market performance for these companies.
- Maviret Indication Expansion: AbbVie announced that its antiviral drug Maviret received a positive opinion for use in patients aged three and older with acute hepatitis C, with final authorization expected by Q3 2026, thereby expanding its influence in the liver disease treatment market.
- Keytruda Combination Therapy: Merck's Keytruda was recommended for use in combination with Pfizer's Padcev for muscle-invasive bladder cancer that cannot be surgically removed, which is expected to enhance its competitive position in the oncology market, with a final decision anticipated by Q3 2026.
- Trodelvy Label Expansion: Gilead's Trodelvy received a positive opinion for treating adults with unresectable triple-negative breast cancer, with a final decision on the label expansion expected later this year, further solidifying Gilead's position in the oncology drug market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.880
Low
95.00
Averages
119.53
High
139.00
Current: 115.880
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
H.C. Wainwright Downgrades Summit to Neutral Amid Trial Concerns
- Rating Downgrade: H.C. Wainwright downgraded Summit Therapeutics (SMMT) from Buy to Neutral, primarily due to concerns over the new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck in partnership with Kelun-Biotech.
- Clinical Trial Results: According to an ASCO abstract, the combination of sac-TMT and Merck's Keytruda reduced the risk of disease progression or death by 65% in lung cancer patients, demonstrating a statistically significant effect that could impact SMMT's market performance.
- Competitive Pressure: Analysts noted that Merck now has a credible defense for Keytruda's market position, particularly against Summit's ivonescimab, which previously showed strong performance in similar clinical settings.
- Delayed Survival Data: Concerns were raised regarding Akeso's delay in updating overall survival data, which, while showing favorable early trends, lacks statistical significance and is now expected to be released in 2026, potentially increasing market uncertainty.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
EU Drug Regulator Panel Endorses Eight New Medicines for Approval
- New Drug Approvals: The EU drug regulator's expert panel endorsed eight new medicines this week, including Merck's Keytruda and AstraZeneca's Enhertu, indicating a positive outlook for cancer treatment advancements that could enhance market performance for these companies.
- Maviret Indication Expansion: AbbVie announced that its antiviral drug Maviret received a positive opinion for use in patients aged three and older with acute hepatitis C, with final authorization expected by Q3 2026, thereby expanding its influence in the liver disease treatment market.
- Keytruda Combination Therapy: Merck's Keytruda was recommended for use in combination with Pfizer's Padcev for muscle-invasive bladder cancer that cannot be surgically removed, which is expected to enhance its competitive position in the oncology market, with a final decision anticipated by Q3 2026.
- Trodelvy Label Expansion: Gilead's Trodelvy received a positive opinion for treating adults with unresectable triple-negative breast cancer, with a final decision on the label expansion expected later this year, further solidifying Gilead's position in the oncology drug market.
See More
EU Regulators Support KEYTRUDA and Padcev Combination Therapy
- Clinical Trial Results: The Phase 3 trial data shows that the KEYTRUDA and Padcev combination significantly improved survival and tumor response in high-risk bladder cancer patients, reducing the risk of disease progression and death by approximately 60% and 50%, respectively, compared to surgery alone.
- Market Potential: If approved, this regimen would become the first PD-1 inhibitor and antibody-drug conjugate combination available in the EU for patients with resectable muscle-invasive bladder cancer, addressing a significant unmet need in treatment options.
- Regulatory Process: The treatment has received a positive opinion from the European Medicines Agency, and is now awaiting final review by the European Commission, with a ruling expected in the third quarter of this year, which could further enhance Merck's market position.
- Investor Reaction: Merck (MRK) shares rose nearly 5% in early trading, reflecting positive market sentiment towards the treatment, and the stock has increased nearly 59% over the past 12 months, indicating strong investor confidence.
See More
Kelun-Biotech's Antibody Drug Surpasses Merck in Lung Cancer Trial
- Clinical Trial Results: Kelun-Biotech's antibody drug sac-TMT outperformed Merck's Keytruda in a late-stage trial for lung cancer, reducing the risk of disease progression or death by 65%, indicating a significant clinical impact that could reshape first-line treatment options for lung cancer.
- Data Presentation Opportunity: The trial results will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, enhancing Kelun-Biotech's visibility in international markets and laying the groundwork for future market promotion.
- Safety Analysis: Approximately 55% of patients treated with sac-TMT experienced treatment-emergent adverse events classified as Grade 3 or higher, compared to only 31% in the control group, indicating that the drug's tolerability requires further evaluation.
- Market Expansion Potential: Based on OptiTROP-Lung05 data, Kelun-Biotech is seeking priority review in China to expand sac-TMT's label as a first-line therapy for lung cancer, which, if approved, would significantly enhance its market share and competitiveness.
See More
Merck's KEYTRUDA Combination Therapy Recommended for Bladder Cancer Approval
- Therapy Recommendation: The European Medicines Agency's Committee has adopted a positive opinion recommending Merck's KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer, marking a significant advancement in clinical application.
- Clinical Trial Basis: This recommendation is based on results from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas, demonstrating the efficacy and safety of this combination therapy for specific patient populations.
- Market Authorization Review: The recommendation will be reviewed by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected by Q3 2026, potentially impacting future market access.
- Positive Stock Market Reaction: In pre-market trading on the NYSE, Merck shares rose by 2.57% to $118.85, reflecting market optimism regarding the approval prospects of this therapy.
See More
H.C. Wainwright Downgrades Summit to Neutral Amid Trial Concerns
- Rating Downgrade: H.C. Wainwright downgraded Summit Therapeutics (SMMT) from Buy to Neutral, primarily due to concerns over the new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck in partnership with Kelun-Biotech.
- Clinical Trial Results: According to an ASCO abstract, the combination of sac-TMT and Merck's Keytruda reduced the risk of disease progression or death by 65% in lung cancer patients, demonstrating a statistically significant effect that could impact SMMT's market performance.
- Competitive Pressure: Analysts noted that Merck now has a credible defense for Keytruda's market position, particularly against Summit's ivonescimab, which previously showed strong performance in similar clinical settings.
- Delayed Survival Data: Concerns were raised regarding Akeso's delay in updating overall survival data, which, while showing favorable early trends, lacks statistical significance and is now expected to be released in 2026, potentially increasing market uncertainty.
See More
US Stocks Rise as Market Optimism Grows
- Strong Market Performance: The S&P 500 rose by 0.54%, the Nasdaq 100 increased by 0.53%, and the Dow Jones Industrial Average reached an all-time high, reflecting market optimism regarding a potential peace deal between the US and Iran, which could boost investor confidence.
- Software Stocks Lead Gains: Workday's stock surged over 8% after reporting Q1 adjusted EPS of $2.66, exceeding the consensus of $2.51, and forecasting Q2 subscription revenue of $2.46 billion, further enhancing confidence in the software sector.
- Oil Price Volatility Affects Markets: Crude oil prices dipped slightly as Qatar coordinated with the US to send a negotiating team to Tehran, raising concerns about future supply; the IEA warned that global oil inventories will remain tight, potentially impacting overall economic growth.
- International Markets Rebound: The Euro Stoxx 50 climbed 1.23%, China's Shanghai Composite rose 0.87%, and Japan's Nikkei increased by 2.68%, indicating a global market optimism that may provide support for the US market.
See More
EU Drug Regulator Panel Endorses Eight New Medicines for Approval
- New Drug Approvals: The EU drug regulator's expert panel endorsed eight new medicines this week, including Merck's Keytruda and AstraZeneca's Enhertu, indicating a positive outlook for cancer treatment advancements that could enhance market performance for these companies.
- Maviret Indication Expansion: AbbVie announced that its antiviral drug Maviret received a positive opinion for use in patients aged three and older with acute hepatitis C, with final authorization expected by Q3 2026, thereby expanding its influence in the liver disease treatment market.
- Keytruda Combination Therapy: Merck's Keytruda was recommended for use in combination with Pfizer's Padcev for muscle-invasive bladder cancer that cannot be surgically removed, which is expected to enhance its competitive position in the oncology market, with a final decision anticipated by Q3 2026.
- Trodelvy Label Expansion: Gilead's Trodelvy received a positive opinion for treating adults with unresectable triple-negative breast cancer, with a final decision on the label expansion expected later this year, further solidifying Gilead's position in the oncology drug market.
See More
EU Regulators Support KEYTRUDA and Padcev Combination Therapy
- Clinical Trial Results: The Phase 3 trial data shows that the KEYTRUDA and Padcev combination significantly improved survival and tumor response in high-risk bladder cancer patients, reducing the risk of disease progression and death by approximately 60% and 50%, respectively, compared to surgery alone.
- Market Potential: If approved, this regimen would become the first PD-1 inhibitor and antibody-drug conjugate combination available in the EU for patients with resectable muscle-invasive bladder cancer, addressing a significant unmet need in treatment options.
- Regulatory Process: The treatment has received a positive opinion from the European Medicines Agency, and is now awaiting final review by the European Commission, with a ruling expected in the third quarter of this year, which could further enhance Merck's market position.
- Investor Reaction: Merck (MRK) shares rose nearly 5% in early trading, reflecting positive market sentiment towards the treatment, and the stock has increased nearly 59% over the past 12 months, indicating strong investor confidence.
See More
Kelun-Biotech's Antibody Drug Surpasses Merck in Lung Cancer Trial
- Clinical Trial Results: Kelun-Biotech's antibody drug sac-TMT outperformed Merck's Keytruda in a late-stage trial for lung cancer, reducing the risk of disease progression or death by 65%, indicating a significant clinical impact that could reshape first-line treatment options for lung cancer.
- Data Presentation Opportunity: The trial results will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, enhancing Kelun-Biotech's visibility in international markets and laying the groundwork for future market promotion.
- Safety Analysis: Approximately 55% of patients treated with sac-TMT experienced treatment-emergent adverse events classified as Grade 3 or higher, compared to only 31% in the control group, indicating that the drug's tolerability requires further evaluation.
- Market Expansion Potential: Based on OptiTROP-Lung05 data, Kelun-Biotech is seeking priority review in China to expand sac-TMT's label as a first-line therapy for lung cancer, which, if approved, would significantly enhance its market share and competitiveness.
See More
Merck's KEYTRUDA Combination Therapy Recommended for Bladder Cancer Approval
- Therapy Recommendation: The European Medicines Agency's Committee has adopted a positive opinion recommending Merck's KEYTRUDA in combination with Padcev for adults with resectable muscle-invasive bladder cancer, marking a significant advancement in clinical application.
- Clinical Trial Basis: This recommendation is based on results from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas, demonstrating the efficacy and safety of this combination therapy for specific patient populations.
- Market Authorization Review: The recommendation will be reviewed by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected by Q3 2026, potentially impacting future market access.
- Positive Stock Market Reaction: In pre-market trading on the NYSE, Merck shares rose by 2.57% to $118.85, reflecting market optimism regarding the approval prospects of this therapy.
See More
